Halozyme Therapeutics HALO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $376.71M-16.6% | $451.77M+27.5% | $354.26M+8.8% | $325.72M+23.0% | $264.86M-11.1% | ||
| $79.24M+0.6% | $78.77M+42.6% | $55.24M+19.2% | $46.36M-4.2% | $48.4M+15.1% | ||
| $297.47M-20.2% | $373M+24.7% | $299.02M+7.0% | $279.36M+29.1% | $216.46M-15.4% | ||
| 79%-3.6pp | 82.6%-1.8pp | 84.4%-1.4pp | 85.8%+4.0pp | 81.7%-4.2pp | ||
| $25.56M-19.9% | $31.9M+84.9% | $17.25M-1.7% | $17.54M+18.5% | $14.8M-27.6% | ||
| $57.88M-24.9% | $77.03M+67.1% | $46.09M+10.8% | $41.61M-1.8% | $42.36M+0.3% | ||
| $16.64M— | —— | $12.16M0.0% | $12.16M+13.9% | $10.67M— | ||
| $3.1M— | —— | $2.1M+5.0% | $2M0.0% | $2M— | ||
| $4.22M-93.8% | $68.58M+2,440% | $2.7M0.0% | $2.7M+0.5% | $2.69M-95.8% | ||
| —— | $12.18M0.0% | $12.18M0.0% | $12.18M0.0% | $12.18M— | ||
| $192.19M-64.7% | $544.66M+299% | $136.34M+10.6% | $123.28M0.0% | $123.33M+0.7% | ||
| $184.52M— | —— | $217.92M+7.6% | $202.44M+43.0% | $141.54M-19.4% | ||
| 49%— | —— | 61.5%-0.6pp | 62.2%+8.7pp | 53.4%-5.5pp | ||
| $5.51M+12.2% | $4.91M+14.3% | $4.3M-2.2% | $4.39M-2.9% | $4.53M-0.3% | ||
| $1.32M-45.8% | $2.43M-54.4% | $5.33M-22.6% | $6.89M+1.1% | $6.82M-6.0% | ||
| $180.33M— | —— | $218.96M+6.8% | $204.94M+42.5% | $143.83M-19.3% | ||
| $30.28M-25.7% | $40.74M-6.8% | $43.73M+9.9% | $39.78M+54.6% | $25.73M-37.5% | ||
| $150.05M— | —— | $175.23M+6.1% | $165.16M+39.9% | $118.1M-13.8% | ||
| 39.8%— | —— | 49.5%-1.2pp | 50.7%+6.1pp | 44.6%-1.4pp | ||
| $1.22— | —— | $1.43+7.5% | $1.33+43.0% | $0.93-12.3% | ||
| $1.27— | —— | $1.49+9.6% | $1.36+41.7% | $0.96-11.1% | ||
| 122.9M-0.8% | 123.9M+1.3% | 122.3M-1.5% | 124.2M-2.0% | 126.6M-2.1% | ||
| 118.1M-1.4% | 119.8M+2.2% | 117.2M-3.4% | 121.3M-1.5% | 123.2M-2.8% | ||
| $30K— | —— | $357K-68.5% | $1.13M-33.6% | $1.71M— | ||
| $17M— | —— | $12.16M0.0% | $12.16M+13.9% | $10.67M— | ||
| $16.64M— | —— | $12.16M0.0% | $12.16M+13.9% | $10.67M— | ||
| $2.25M— | —— | $1.86M+0.3% | $1.85M+0.3% | $1.85M— | ||
| $29.51M+26.2% | $23.38M+31.6% | $17.76M0.0% | $17.76M0.0% | $17.76M0.0% | ||
| 27.9M— | —— | 21.9M-10.2% | 24.4M+1.2% | 24.1M— | ||
| $1.75M+1,980% | $84K-84.4% | $537K— | —— | $488K— | ||
| $175.59M— | —— | $357.8M+413% | -$114.47M-289% | $60.48M— | ||
| $155.44M— | —— | $181.37M+29.4% | $140.17M+26.4% | $110.85M— | ||
| -$214K— | —— | -$170K+33.9% | -$257K-1.6% | -$253K— | ||
| $0.17— | —— | $0.2+4.1% | $0.19+8.4% | $0.18— | ||
| $1.96M— | —— | $0— | $0— | $0— | ||
| -$24.92M-174% | $33.85M+572% | -$7.16M+75.9% | -$29.69M-422% | $9.22M-81.6% | ||
| $19.55M-78.4% | $90.48M+205% | $29.7M+153% | $11.72M+406% | -$3.83M-117% | ||
| -$3.43M— | —— | -$27.35M-486% | $7.09M+148% | $2.86M— | ||
| -$27.38M-45.8% | -$18.78M-1,806% | $1.1M-92.4% | $14.54M+2,381% | $586K-92.4% | ||
| $9.11M— | —— | $20.32M-43.7% | $36.07M+622% | $5M+189% | ||
| -$1.61M— | —— | -$22.4M+92.5% | -$298.97M-8,902% | -$3.32M+98.7% | ||
| -$2.88M+99.6% | -$741.79M-468% | $201.61M— | —— | -$90.42M— | ||
| $180.08M-17.8% | $219.03M+22.6% | $178.6M+79.1% | $99.71M-35.3% | $154.22M-13.6% | ||
| 1— | —— | —— | —— | 1— | ||
| $700K— | —— | $600K+20.0% | $500K0.0% | $500K— | ||
| $2.9M— | —— | $1.9M+5.6% | $1.8M0.0% | $1.8M— | ||
| $2.6M— | —— | $1.5M0.0% | $1.5M0.0% | $1.5M— | ||
| $5.39M— | —— | $6.15M+125% | -$24.99M-245% | -$7.24M— | ||
| $1.33M— | —— | $2.17M+3.3% | $2.1M+1,107% | -$208K— | ||
| $4.02M— | —— | $3.67M+114% | -$27.05M-274% | -$7.22M— | ||
| $45K— | —— | -$3K0.0% | -$3K— | $0— | ||
| -$3K— | —— | $312K+991% | -$35K-119% | $189K— | ||
| $1.32M-45.8% | $2.43M-54.4% | $5.33M-22.6% | $6.89M+1.1% | $6.82M-6.0% | ||
| —— | —— | —— | —— | —— | ||
| $1.61M— | —— | —— | —— | $3.32M— | ||
| $8.85M— | $0-100% | $4.96M-95.2% | $102.76M-26.4% | $139.64M+171% | ||
| $3.74M+162% | $1.43M-52.9% | $3.03M+93.9% | $1.56M+64.5% | $950K-68.9% | ||
| $710K— | —— | —— | —— | $0— | ||
| $9M— | —— | $209.6M+10.8% | $189.11M+277% | $50.17M— | ||
| —— | $71.22M0.0% | $71.22M0.0% | $71.22M0.0% | $71.22M— | ||
| —— | $20.37M0.0% | $20.37M0.0% | $20.37M0.0% | $20.37M+3.1% | ||
| $376.71M-16.6% | $451.77M+27.5% | $354.26M+8.8% | $325.72M+23.0% | $264.86M-11.1% | ||
| 10— | —— | —— | —— | 10— | ||
| $16.64M+0.4% | $16.57M+36.3% | $12.16M0.0% | $12.16M+13.9% | $10.67M-6.9% | ||
| 300K— | —— | —— | —— | 400K— | ||
| 3.8%— | —— | 3.8%0.0% | 3.8%-0.5% | 4.3%— | ||
| 3.6%— | —— | 3.7%-0.1% | 3.8%-0.5% | 4.3%— | ||
| 0%— | —— | 0%— | 0%— | 0%— | ||
| -$1.61M— | —— | $16.48M+264% | $4.52M+236% | -$3.32M— | ||
| —— | —— | $38.84M-87.3% | $306.38M+125,664% | -$244K— | ||
| $184.52M— | —— | $217.92M+7.6% | $202.44M+43.0% | $141.54M-19.4% | ||
| $188.74M— | —— | $220.62M+7.5% | $205.14M+42.2% | $144.22M-19.0% | ||
| $188.74M— | —— | $220.62M+7.5% | $205.14M+42.2% | $144.22M-19.0% | ||
| 50.1%— | —— | 62.3%-0.7pp | 63%+8.5pp | 54.5%-5.3pp | ||
| $184.52M— | —— | $217.92M+7.6% | $202.44M+43.0% | $141.54M-19.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Halozyme Therapeutics's revenue?
- Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.
- Is Halozyme Therapeutics profitable?
- Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.
- What are Halozyme Therapeutics's profit margins?
- Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.
- What is Halozyme Therapeutics's earnings per share?
- Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.
- Where does Halozyme Therapeutics's income statement data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
